Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets.
In this study, metformin hydrochloride (MH) sustained-release pellets were successfully prepared by centrifugal granulation. Seed cores preparation, drug layering, talc modification and coating of polymeric suspensions were carried out in a centrifugal granulator. Talc modification was performed before coating in order to overcome the high water solubility of metformin. The influence of surface modification by talc, the effects of Eudragit types and ratios, as well as the correlation between in vitro release and in vivo absorption were investigated in detail. Experimental results indicated that talc modification made a decisive contribution to controlling the drug release by avoiding drug dumping. Three dissolution media: 0.1 M HCl, distilled water and pH 6.8 phosphate buffer were employed to determine the in vitro release behaviors of the above metformin hydrochloride pellets. The relative bioavailability of the sustained-release pellets was studied in 12 healthy volunteers after oral administration in a fast state using a commercially available immediate release tablet (Glucophage) as a reference. Following coating with a blend of Eudragit L30D-55 and Eudragit NE30D (1:20), at 7% or 10% coating level, respectively (referred to as F-2, F-3), the pellets acquired perfect sustained-release properties and good relative bioavailability. The Cmax, Tmax and relative bioavailability for F-2 and F-3 coated pellets were 1.21 microg/ml, 6 h, 97.6% and 1.65 microg/ml, 8 h, 165%, respectively. Combined use of two Eudragit polymers with different features as coating materials produced the desired results. Restricted delivery of metformin hydrochloride to the small intestine from differently coated pellets resulted in increased relative bioavailability and a sustained release effect. The adoption of several different pH dissolution media established a better relationship between the in vitro release and in vivo absorption of the sustained-release pellets.
Hu
Lian-Dong
LD
College of Pharmacy, Hebei University, Baoding, PR China. hldrenew@yahoo.com.cn
Liu
Yang
Y
Tang
Xing
X
Zhang
Qian
Q
D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D020099:Coated Materials, Biocompatible / Q000737:chemistry / Q000493:pharmacokinetics; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008689:Methacrylates / Q000737:chemistry; D011108:Polymers / Q000737:chemistry; D012995:Solubility; D013607:Tablets; D013627:Talc / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods*
D020099:Coated Materials, Biocompatible; D003692:Delayed-Action Preparations; C477852:Eudragit L 30 D-55; C477853:Eudragit NE 30-D; D007004:Hypoglycemic Agents; D008689:Methacrylates; D011108:Polymers; D013607:Tablets; D013627:Talc; C008384:methacrylic acid; D008687:Metformin